Human Genomics (Jun 2024)

Germline mutations of breast cancer susceptibility genes through expanded genetic analysis in unselected Colombian patients

  • Diana Carolina Sierra-Díaz,
  • Adrien Morel,
  • Dora Janeth Fonseca-Mendoza,
  • Nora Contreras Bravo,
  • Nicolas Molano-Gonzalez,
  • Mariana Borras,
  • Isabel Munevar,
  • Mauricio Lema,
  • Henry Idrobo,
  • Daniela Trujillo,
  • Norma Serrano,
  • Ana Isabel Orduz,
  • Diego Lopera,
  • Jaime González,
  • Gustavo Rojas,
  • Paula Londono-De Los Ríos,
  • Ray Manneh,
  • Rodrigo Cabrera,
  • Wilson Rubiano,
  • Jairo de la Peña,
  • María Catalina Quintero,
  • William Mantilla,
  • Carlos M. Restrepo

DOI
https://doi.org/10.1186/s40246-024-00623-7
Journal volume & issue
Vol. 18, no. 1
pp. 1 – 14

Abstract

Read online

Abstract Background In Colombia and worldwide, breast cancer (BC) is the most frequently diagnosed neoplasia and the leading cause of death from cancer among women. Studies predominantly involve hereditary and familial cases, demonstrating a gap in the literature regarding the identification of germline mutations in unselected patients from Latin-America. Identification of pathogenic/likely pathogenic (P/LP) variants is important for shaping national genetic analysis policies, genetic counseling, and early detection strategies. The present study included 400 women with unselected breast cancer (BC), in whom we analyzed ten genes, using Whole Exome Sequencing (WES), know to confer risk for BC, with the aim of determining the genomic profile of previously unreported P/LP variants in the affected population. Additionally, Multiplex Ligation-dependent Probe Amplification (MLPA) was performed to identify Large Genomic Rearrangements (LGRs) in the BRCA1/2 genes. To ascertain the functional impact of a recurrent intronic variant (ATM c.5496 + 2_5496 + 5delTAAG), a minigene assay was conducted. Results We ascertained the frequency of P/LP germline variants in BRCA2 (2.5%), ATM (1.25%), BRCA1 (0.75%), PALB2 (0.50%), CHEK2 (0.50%), BARD1 (0.25%), and RAD51D (0.25%) genes in the population of study. P/LP variants account for 6% of the total population analyzed. No LGRs were detected in our study. We identified 1.75% of recurrent variants in BRCA2 and ATM genes. One of them corresponds to the ATM c.5496 + 2_5496 + 5delTAAG. Functional validation of this variant demonstrated a splicing alteration probably modifying the Pincer domain and subsequent protein structure. Conclusion This study described for the first time the genomic profile of ten risk genes in Colombian women with unselected BC. Our findings underscore the significance of population-based research, advocating the consideration of molecular testing in all women with cancer.

Keywords